About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 102819, 11 pages
http://dx.doi.org/10.1155/2013/102819
Review Article

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors

1Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China
2Department of Nuclear Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325003, China
3Zhejiang University Medical PET Center, Zhejiang University, Hangzhou, Zhejiang 310009, China
4Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, Zhejiang 310009, China
5Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, Zhejiang 310009, China
6Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China

Received 17 July 2013; Accepted 8 August 2013

Academic Editor: Mei Tian

Copyright © 2013 Ling Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. P. Koopmans, O. N. Neels, I. P. Kema et al., “Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results,” Critical Reviews in Oncology/Hematology, vol. 71, no. 3, pp. 199–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Rufini, M. L. Calcagni, and R. P. Baum, “Imaging of neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 36, no. 3, pp. 228–247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Capella, P. U. Heirz, H. Hofler, E. Solcia, and G. Kloppel, “Revised classification of neuroendocrine tumours of the lung, pancreas and gut,” Virchows Archiv, vol. 425, no. 6, pp. 547–560, 1995. View at Scopus
  4. E. Bombardieri, M. Maccauro, E. De Deckere, G. Savelli, and A. Chiti, “Nuclear medicine imaging of neuroendocrine tumours,” Annals of Oncology, vol. 12, supplement 2, pp. S51–S61, 2001. View at Scopus
  5. V. Ambrosini, D. Campana, P. Tomassetti, G. Grassetto, D. Rubello, and S. Fanti, “PET/CT with 68Gallium-DOTA-peptides in NET: an overview,” European Journal of Radiology, vol. 80, no. 2, pp. e116–e119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Stoyianni, G. Pentheroudakis, and N. Pavlidis, “Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors,” Cancer Treatment Reviews, vol. 37, no. 5, pp. 358–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. I. M. Modlin, K. D. Lye, and M. Kidd, “A 5-decade analysis of 13,715 carcinoid tumors,” Cancer, vol. 97, no. 4, pp. 934–959, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. D. P. Lindholm and K. Oberg, “Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors,” Hormone and Metabolic Research, vol. 43, no. 12, pp. 832–837, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Oberg, “Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract,” Current Opinion in Oncology, vol. 6, no. 4, pp. 441–451, 1994. View at Scopus
  10. V. E. Strong, T. Kennedy, H. Al-Ahmadie et al., “Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis,” Surgery, vol. 143, no. 6, pp. 759–768, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. U.-F. Pape, U. Berndt, J. Müller-Nordhorn et al., “Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours,” Endocrine-Related Cancer, vol. 15, no. 4, pp. 1083–1097, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Sundin and A. Rockall, “Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead,” Neuroendocrinology, vol. 96, no. 4, pp. 261–271, 2012. View at Publisher · View at Google Scholar
  13. Y. C. Patel, “Somatostatin and its receptor family,” Frontiers in Neuroendocrinology, vol. 20, no. 3, pp. 157–198, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Brazeau, J. Epelbaum, and G. S. Tannenbaum, “Somatostatin: isolation, characterization, distribution, and blood determination,” Metabolism, vol. 27, no. 9, pp. 1133–1137, 1978. View at Scopus
  15. D. Hoyer, G. I. Bell, M. Berelowitz et al., “Classification and nomenclature of somatostatin receptors,” Trends in Pharmacological Sciences, vol. 16, no. 3, pp. 86–88, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. J. C. Reubi, B. Waser, J.-C. Schaer, and J. A. Laissue, “Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands,” European Journal of Nuclear Medicine, vol. 28, no. 7, pp. 836–846, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. S. W. J. Lamberts, W. H. Bakker, J.-C. Reubi, and E. P. Krenning, “Somatostatin-receptor imaging in the localization of endocrine tumors,” The New England Journal of Medicine, vol. 323, no. 18, pp. 1246–1249, 1990. View at Scopus
  18. J. C. Reubi, L. Kvols, E. Krenning, and S. W. J. Lamberts, “Distribution of somatostatin receptors in normal and tumor tissue,” Metabolism, vol. 39, no. 9, pp. 78–81, 1990. View at Publisher · View at Google Scholar · View at Scopus
  19. E. P. Krenning, D. J. Kwekkeboom, W. H. Bakker et al., “Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients,” European Journal of Nuclear Medicine, vol. 20, no. 8, pp. 716–731, 1993. View at Scopus
  20. J. C. Reubi and H. R. Maecke, “Peptide-based probes for cancer imaging,” Journal of Nuclear Medicine, vol. 49, no. 11, pp. 1735–1738, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. W. W. De Herder, L. J. Hofland, A. J. Van Der Lely, and S. W. J. Lamberts, “Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours,” Endocrine-Related Cancer, vol. 10, no. 4, pp. 451–458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Papotti, M. Bongiovanni, M. Volante et al., “Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis,” Virchows Archiv, vol. 440, no. 5, pp. 461–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Bodei, M. Cremonesi, C. Grana et al., “Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 7, pp. 1038–1046, 2004. View at Scopus
  24. A. Al-Nahhas, Z. Win, T. Szyszko et al., “Gallium-68 PET: a new frontier in receptor cancer imaging,” Anticancer Research, vol. 27, no. 6 B, pp. 4087–4094, 2007. View at Scopus
  25. K. K. Wong, R. T. Waterfield, M. C. Marzola et al., “Contemporary nuclear medicine imaging of neuroendocrine tumours,” Clinical Radiology, vol. 67, no. 11, pp. 1035–1050, 2012. View at Publisher · View at Google Scholar
  26. N. Naswa and C. S. Bal, “Divergent role of 68Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience,” Recent Results in Cancer Research, vol. 194, pp. 321–351, 2012.
  27. W. W. de Herder, D. J. Kwekkeboom, R. A. Feelders et al., “Somatostatin receptor imaging for neuroendocrine tumors,” Pituitary, vol. 9, no. 3, pp. 243–248, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Srirajaskanthan, I. Kayani, A. M. Quigley, J. Soh, M. E. Caplin, and J. Bomanji, “The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy,” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 875–882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. De Jong, W. H. Bakker, E. P. Krenning et al., “Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy,” European Journal of Nuclear Medicine, vol. 24, no. 4, pp. 368–371, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. D. J. Kwekkeboom and E. P. Krenning, “Somatostatin receptor imaging,” Seminars in Nuclear Medicine, vol. 32, no. 2, pp. 84–91, 2002. View at Scopus
  31. M. Schmidt, E. Fischer, M. Dietlein et al., “Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas,” European Journal of Nuclear Medicine, vol. 29, no. 12, pp. 1571–1580, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. T. D. Poeppel, I. Binse, S. Petersenn et al., “68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 52, no. 12, pp. 1864–1870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Kayani, J. B. Bomanji, A. Groves et al., “Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG,” Cancer, vol. 112, no. 11, pp. 2447–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Kayani, B. G. Conry, A. M. Groves et al., “A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 50, no. 12, pp. 1927–1932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Kowalski, M. Henze, J. Schuhmacher, H. R. Mäcke, M. Hofmann, and U. Haberkorn, “Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3-octreotidein comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors,” Molecular Imaging and Biology, vol. 5, no. 1, pp. 42–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Gabriel, C. Decristoforo, D. Kendler et al., “68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT,” Journal of Nuclear Medicine, vol. 48, no. 4, pp. 508–518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. T. D. Poeppel, I. Binse, S. Petersenn et al., “68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 52, no. 12, pp. 1864–1870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Desai, J. Watkins, N. Woodward et al., “Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin,” Journal of Clinical Gastroenterology, vol. 45, no. 1, pp. e8–e11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Wild, H. R. Mäcke, B. Waser et al., “68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 6, p. 724, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Pfeifer, U. Knigge, J. Mortensen et al., “Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study,” Journal of Nuclear Medicine, vol. 53, no. 8, pp. 1207–1215, 2012.
  41. H. J. Wester, M. Schottelius, K. Scheidhauer et al., “PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 1, pp. 117–122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Meisetschläger, T. Poethko, A. Stah et al., “Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide,” Journal of Nuclear Medicine, vol. 47, no. 4, pp. 566–573, 2006. View at Scopus
  43. G. Treglia, P. Castaldi, G. Rindi, A. Giordano, and V. Rufini, “Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis,” Endocrine, vol. 42, pp. 80–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Ambrosini, D. Campana, L. Bodei et al., “68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 51, no. 5, pp. 669–673, 2010. View at Scopus
  45. A. R. Haug, C. J. Auernhammer, B. Wängler et al., “68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1349–1356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Kaltsas, A. Rockall, D. Papadogias, R. Reznek, and A. B. Grossman, “Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours,” European Journal of Endocrinology, vol. 151, no. 1, pp. 15–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. D. J. Kwekkeboom, J. J. Teunissen, W. H. Bakker et al., “Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2754–2762, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Oh, V. Prasad, D. S. Lee, and R. P. Baum, “Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18FDG PET/CT,” International Journal of Molecular Imaging, vol. 2011, Article ID 524130, 7 pages, 2011. View at Publisher · View at Google Scholar
  49. J. B. Cwikla, A. Sankowski, N. Seklecka et al., “Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study,” Annals of Oncology, vol. 21, no. 4, pp. 787–794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Ezziddin, J. Lohmar, C. J. Yong-Hing et al., “Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?” Clinical Nuclear Medicine, vol. 37, pp. e141–e147, 2012.
  51. S. Koukouraki, L. G. Strauss, V. Georgoulias, M. Eisenhut, U. Haberkorn, and A. Dimitrakopoulou-Strauss, “Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 10, pp. 1115–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Koukouraki, L. G. Strauss, V. Georgoulias et al., “Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 4, pp. 460–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Waldherr, M. Pless, H. R. Maecke et al., “Tumor response and clinical benefit in neuroendocrine tumors after 7.4 Gbq 90Y-DOTATOC,” Journal of Nuclear Medicine, vol. 43, no. 5, pp. 610–616, 2002. View at Scopus
  54. G. Savelli, F. Bertagna, F. Franco et al., “Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide,” Cancer, vol. 118, pp. 2915–2924, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Van Essen, E. P. Krenning, M. De Jong, R. Valkema, and D. J. Kwekkeboom, “Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours,” Acta Oncologica, vol. 46, no. 6, pp. 723–734, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Nisa, G. Savelli, and R. Giubbini, “Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review,” Annals of Nuclear Medicine, vol. 25, no. 2, pp. 75–85, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Valkema, S. Pauwels, L. K. Kvols et al., “Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 36, no. 2, pp. 147–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Forrer, C. Waldherr, H. R. Maecke, and J. Mueller-Brand, “Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors,” Anticancer Research, vol. 26, no. 1 B, pp. 703–707, 2006. View at Scopus
  59. A. Sowa-Staszczak, D. Pach, J. Kunikowska et al., “Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours,” Endokrynologia Polska, vol. 62, no. 5, pp. 392–400, 2011. View at Scopus
  60. D. J. Kwekkeboom, W. W. De Herder, B. L. Kam et al., “Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. P. Esser, E. P. Krenning, J. J. M. Teunissen et al., “Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 11, pp. 1346–1351, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Forrer, H. Uusijärvi, D. Storch, H. R. Maecke, and J. Mueller-Brand, “Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC,” Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1310–1316, 2005. View at Scopus
  63. G. A. Kaltsas, D. Papadogias, P. Makras, and A. B. Grossman, “Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 683–699, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. U. Garske, M. Sandstrom, S. Johansson et al., “Lessons on tumour response: imaging during therapy with 177Lu-DOTA-octreotate. a case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma,” Theranostics, vol. 2, pp. 459–471, 2012.
  65. B. L. Kam, J. J. Teunissen, E. P. Krenning et al., “Lutetium-labelled peptides for therapy of neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, supplement 1, pp. S103–S112, 2012.
  66. D. J. Kwekkeboom, W. H. Bakker, B. L. Kam et al., “Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 3, pp. 417–422, 2003. View at Scopus
  67. D. J. Kwekkeboom, W. W. de Herder, C. H. J. van Eijck et al., “Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 40, no. 2, pp. 78–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Van Essen, E. P. Krenning, B. L. Kam, W. W. De Herder, M. O. Van Aken, and D. J. Kwekkeboom, “Report on short-term side effects of treatments with 177Lu- octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 4, pp. 743–748, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Kunikowska, L. Królicki, A. Hubalewska-Dydejczyk, R. Mikolajczak, A. Sowa-Staszczak, and D. Pawlak, “Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem90 Y/177Lu-DOTATATE: which is a better therapy option?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 10, pp. 1788–1797, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Sainz-Esteban, V. Prasad, C. Schuchardt, C. Zachert, J. M. Carril, and R. P. Baum, “Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 3, pp. 501–511, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Valkema, S. A. Pauwels, L. K. Kvols et al., “Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0,Tyr3-octreotate,” Journal of Nuclear Medicine, supplement 1, pp. 83S–91S, 2005. View at Scopus
  72. K. Öberg, L. Kvols, M. Caplin et al., “Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system,” Annals of Oncology, vol. 15, no. 6, pp. 966–973, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Zhang, M. A. Moroz, I. Serganova et al., “Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC,” Journal of Nuclear Medicine, vol. 52, no. 1, pp. 123–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Cremonesi, M. Ferrari, S. Zoboli et al., “Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC,” European Journal of Nuclear Medicine, vol. 26, no. 8, pp. 877–886, 1999. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Pach, A. Sowa-Staszczak, J. Kunikowska et al., “Repeated cycles of peptide receptor radionuclide therapy (PRRT)—results and side-effects of the radioisotope 90Y-DOTA TATE,177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET,” Radiotherapy and Oncology, vol. 102, no. 1, pp. 45–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. D. J. Kwekkeboom, B. L. Kam, M. Van Essen et al., “Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors,” Endocrine-Related Cancer, vol. 17, no. 1, pp. R53–R73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. K. R. Zinn and T. R. Chaudhuri, “The type 2 human somatostatin receptor as a platform for reporter gene imaging,” European Journal of Nuclear Medicine, vol. 29, no. 3, pp. 388–399, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. B. E. Rogers, J. J. Parry, R. Andrews, P. Cordopatis, B. A. Nock, and T. Maina, “MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and 94mTc-demotate 1,” Journal of Nuclear Medicine, vol. 46, no. 11, pp. 1889–1897, 2005. View at Scopus
  79. C. Orlando, C. C. Raggi, L. Bagnoni, R. Sestini, V. Briganti, G. La Cava, et al., “Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide,” Medical and Pediatric Oncology, vol. 36, pp. 224–226, 2001.
  80. V. Briganti, R. Sestini, C. Orlando et al., “Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors,” Clinical Cancer Research, vol. 3, no. 12, pp. 2385–2391, 1997. View at Scopus
  81. G. Cotugno, M. Aurilio, P. Annunziata et al., “Noninvasive repetitive imaging of somatostatin receptor 2 gene transfer with positron emission tomography,” Human Gene Therapy, vol. 22, no. 2, pp. 189–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. V. Kundra, F. Mannting, A. G. Jones, and A. I. Kassis, “Noninvasive monitoring of somatostatin receptor type 2 chimeric gene transfer,” Journal of Nuclear Medicine, vol. 43, no. 3, pp. 406–412, 2002. View at Scopus
  83. K. R. Zinn, D. J. Buchsbaum, T. R. Chaudhuri, J. M. Mountz, W. E. Grizzle, and B. E. Rogers, “Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re,” Journal of Nuclear Medicine, vol. 41, no. 5, pp. 887–895, 2000. View at Scopus
  84. D. J. Buchsbaum, T. R. Chaudhuri, M. Yamamoto, and K. R. Zinn, “Gene expression imaging with radiolabeled peptides,” Annals of Nuclear Medicine, vol. 18, no. 4, pp. 275–283, 2004. View at Scopus
  85. T. R. Chaudhuri, B. E. Rogers, D. J. Buchsbaum, J. M. Mountz, and K. R. Zinn, “A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts,” Gynecologic Oncology, vol. 83, no. 2, pp. 432–438, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. J. J. M. Teunissen, D. J. Kwekkeboom, R. Valkema, and E. P. Krenning, “Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours,” Endocrine-Related Cancer, vol. 18, supplement 1, pp. S27–S51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Belhocine, J. Foidart, P. Rigo et al., “Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67,” Nuclear Medicine Communications, vol. 23, no. 8, pp. 727–734, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Al-Ibraheem, R. A. Bundschuh, J. Notni et al., “Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 11, pp. 2005–2013, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Orlefors, A. Sundin, U. Garske et al., “Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3392–3400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Rajekar, K. Bogammana, and R. S. Stubbs, “Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment,” International Journal of Hepatology, vol. 2011, Article ID 404916, 7 pages, 2011. View at Publisher · View at Google Scholar